BGB-DXP593
- Generic Name
- BGB-DXP593
- Drug Type
- Biotech
- Background
BGB-DXP593 is a SARS-CoV-2 neutralizing antibody. It is currently being investigated against COVID-19 in the clinical trial NCT04551898 (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)) by BeiGene.
BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Participants
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 25
- Registration Number
- NCT04669262
- Locations
- 🇦🇺
Q PHARM, Herston, Queensland, Australia
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 181
- Registration Number
- NCT04551898
- Locations
- 🇺🇸
Btc Network Midland Florida Clinical Research Center, DeLand, Florida, United States
🇺🇸Elixia Clinical Research Collaborative, Hollywood, Florida, United States
🇧🇷Consultoria Medica E Pesquisa Clinica, Sorcaba, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath